Wolf JM, Gubert Borges B, Pereira Fagundes P, de Souza V, Brenner A, Petek H, Michelon dos Santos W, Gasparetto Maccari J, Rohsig V, Parrini Mutlaq M, Nasi LA. Adverse drug events, comorbidities, and older age are statistically more prevalent in COVID-19 hospitalized patients treated with remdesivir than tocilizumab in a private hospital from southern Brazil. Clin Biomed Res [Internet]. 29º de novembro de 2023 [citado 24º de junho de 2025];43(3). Disponível em: https://seer.ufrgs.br/index.php/hcpa/article/view/129384